Brief: Shanghai Public Health Clinical Center Completed Patient Enrollment In Clinical Study Of Pd-L1 Antibody Asc22 (Envafolimab) In Combination With Chidamide For Functional Cure Of HIV Infection
15/09/2022 11:12
Sept 15 (Reuters) - Ascletis Pharma Inc 1672.HK :
* SHANGHAI PUBLIC HEALTH CLINICAL CENTER COMPLETED PATIENT
ENROLLMENT IN CLINICAL STUDY OF PD-L1 ANTIBODY ASC22
(ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE FOR FUNCTIONAL CURE
OF HIV INFECTION
Source text for Eikon: ID:nPn4Lwzlta
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management